

End point title: Number of Subjects With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6

| | |
|---|---|
| Statistical analysis title | Alemtuzumab Treatment CAMMS323 Extension |
| Statistical analysis description | The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method. |
| Comparison groups | Alemtuzumab Treatment CAMMS323 Extension |
| Number of subjects included in analysis | 235 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Method | |
| Parameter type | Percentage with SRD |
| Point estimate | 32.69 |
| Confidence interval | |
| level | 95% |
| sides | 2-sided |
| lower limit | 26.96 |
| upper limit | 39.28 |
| Statistical analysis title | Alemtuzumab Treatment CAMMS324 Extension |
| Statistical analysis description | The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method. |
| Comparison groups | Alemtuzumab Treatment CAMMS324 Extension |
| Number of subjects included in analysis | 321 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Method | |
| Parameter type | Percentage with SRD |
| Point estimate | 42.46 |
| Confidence interval | |
| level | 95% |
| sides | 2-sided |
| lower limit | 37.08 |
| upper limit | 48.28 |